# Berberine and Glycemic Control

Defined berberine can improve short-term T2D glycemic control; modern GLP-1 equivalence, broad weight-loss claims and exact glutathione/NMN stack benefits require separate evidence.

The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator.

Clinical, prediabetes, obesity, liver, PCOS and drug-induced weight contexts were tested, but they do not establish a prospectively mapped boundary within the exact registered pure-berberine, twelve-week adult T2D glycemic claim. Diabetes-free nulls are external scope limits, not a failure inside baseline T2D. Antibiotic pretreatment, ethnicity, formulation, concomitant therapy and durability remain generalization questions. Tolerance-run-in or adherent completers do not redefine broad beneficiaries after outcomes.